Global Prothrombin Complex Concentrates Market, by Type (3-FactorPCC and 4-Factor PCC), by Application (Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, and Others), by End User (Hospital, Ambulatory Surgical Centres and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 771.2 million in 2021 and is expected to exhibit a CAGR of 10.2% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The global prothrombin complex concentrates market is expected to witness significant growth during the forecast period, owing to the increasing number of product approvals and launches by key players.
For instance, in 2014, China Biologics Product Inc., a plasma-based biopharmaceutical company, received approval from China Food and Drug Administration (the ‘CFDA’) for commercial manufacturing of human prothrombin complex concentrate (PCC) at its Shandong Taibang facility.
PCC is used for the prophylaxis and treatment of congenital and acquired clotting factor II, factor VII, factor IX or factor X deficiencies, including those caused by hemophilia and other liver diseases.
Global Prothrombin Complex Concentrates Market - Impact of Coronavirus (Covid-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID 19 pandemic.
Coronavirus pandemic has negatively impacted the development, production, and supply of medicines and also affected growth of the pharmaceutical businesses of various companies across the globe, as COVID-19 pandemic has led to lockdown in several countries, globally. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the pharmaceuticals and kits for diagnostic and therapeutic use.
Thus, COVID-19 pandemic has affected the economy in three main ways; 1) By directly affecting the production and demand; 2) By creating disruptions in distribution channels; and 3) By its financial impact on firms and financial markets.
Supply chain and manufacturing activities in India, China, and the U.S. are disrupted due to global lockdown, while many countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of pharmaceutical drugs from one place to another.
Browse 35 Market Data Tables and 30 Figures spread through 149 Pages and in-depth TOC on “Prothrombin Complex Concentrates Market”- Global Forecast to 2028, by Type (3-FactorPCC and 4-Factor PCC), by Application (Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency and Others), by End User (Hospital, Ambulatory Surgical Centres and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Prothrombin Complex Concentrates Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/prothrombin-complex-concentrates-market-4647
Increasing prevalence of hemophilia B is expected to drive the growth of the prothrombin complex concentrates market.
Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor, factor VIII. There are around 13 types of clotting factors that work with blood platelets to help the clotting.
For instance, according to the Australian Bleeding Disorders Registry, in 2015, there were around 4,941 patients who suffered from common hereditary bleeding disorders, out of which 2,301 patients were diagnosed with hemophilia A, and 548 patients were diagnosed with hemophilia B in Australia.
Key Takeaways of the Global Prothrombin Complex Concentrates Market:
- The global prothrombin complex concentrates market is expected to exhibit a CAGR of 10.2% over the forecast period, owing to increasing product launches. For instance, in 2017, CSL Behring launched Kcentra in Japan. Kcentra is Prothrombin Complex Concentrate (Human), indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist.
- Among End User, Hospital segment is expected to account for the largest market share in 2021 owing to the increasing preference for prothrombin complex concentrates
Key players operating in the global prothrombin complex concentrates market include Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin
